Alok Srivastava, MD, FRACP, FRCPA, FRCP
Christian Medical College - Vellore, India

Alok Srivastava, MD, FRACP, FRCPA. FRCP is Professor in the Department of Haematology, and head of the Centre for Stem Cell Research at the Christian Medical College (CMC), Vellore in India. Dr. Srivastava has been involved with the management of patients with bleeding disorders for over 25 years. His group has worked extensively on developing laboratory methods and clinical protocols that are applicable in developing countries with particular emphasis on cost-sensitive genetic diagnosis protocols for a range of hereditary bleeding disorders, factor replacement therapies, especially for surgical procedures, and meaningful assessment of long-term outcomes. Their current focus is on establishing cost effective models for prophylaxis as well as novel therapies for bleeding disorders including gene therapy. He leads the World Federation of Hemophilia (WFH) designated International Hemophilia Training Center at CMC, Vellore.

Dr. Srivastava currently chairs the steering committee of the Asia Pacific Hemophilia Working Group. He was the Chair of the FVIII/IX Subcommittee of the Scientific and Standardization Committee (SSC), International Society of Thrombosis and Haemostasis (ISTH) from 2006-2010. He currently chairs the task force of the FVIII/IX Subcommittee of the SSC of the ISTH on gene therapy for hemophilia. He was on the board of the WFH from 2002 until 2014 and served as the Vice-President (Medical) from 2012 to 2014. He is the chair of writing group of the WFH guidelines for the management of hemophilia.


Please enable the javascript to submit this form

Supported by educational grants from Bayer, BioMarin, CSL Behring, Freeline Therapeutics Limited, Pfizer Inc., Spark Therapeutics, and uniQure, Inc.

Essential SSL